10月11日，伊妍仕在官微发表声明称，针对被告山东采采医疗科技有限公司、山东谷雨春生物科技有限公司、山东采采医疗科技有限公司上海第一分公司就其注射用聚己内酯微球面部填充剂（商品名“塑妍真·真妤”）商业化行为侵害发明专利权纠纷一案提起民事诉讼，上海知识产权法院已于2024年10月10日正式受理。并于近日向欣可丽美学（杭州）医疗科技有限公司送达了《案件受理通知书》。1. Huadong Medicine's "EeenJoy" claims that Cai Cai Medical's "Suyan Zhen" has infringed on its invention patent rights, and has initiated civil litigation. 2. Cai Cai Medical's parent company, Guyu Chun, has denied this claim. As of now, the time since the launch of "Suyan Zhen" is less than two months. 3. Industry experts believe that it is currently difficult to determine whether Guyu Chun has engaged in infringement.
October 12th, Cailian News Agency (Reporter He Fan) After the monopoly of "Shao Nu Zhen" was broken, whose cake has been affected? Recently, under the umbrella of Huadong Medicine (000963.SZ), "EeenJoy" claimed that the domestic first "Shao Nu Zhen" - Cai Cai Medical's "Suyan Zhen" has infringed on its invention patent rights, and has filed a civil lawsuit. Subsequently, Cai Cai Medical's parent company, Guyu Chun, denied this claim.
It is worth noting that as of now, the time since the launch of "Suyan Zhen" is less than two months. Some industry experts told Cailian News Agency reporters that it is now difficult to define whether Guyu Chun has committed any infringement, and Huadong Medicine's statement this time may be aimed at protecting intellectual property rights and attracting more market attention.
On October 11th, EeenJoy released a statement on its official WeChat account, stating that in the case of the patent infringement dispute over the commercialization of its injection poly caprolactone microsphere facial filler (trade name "Suyan Zhen·Zhen Yu") by the defendants Shandong Cai Cai Medical Technology Co., Ltd., Shandong Guyu Chun Biotechnology Co. Ltd., and Shandong Cai Cai Medical Technology Co., Ltd. Shanghai Branch, a civil lawsuit has been filed. Shanghai Intellectual Property Court has officially accepted the case on October 10th, 2024. And recently, a 'Notice of Case Acceptance' has been served to Xin Keli Mei Xue (Hangzhou) Medical Technology Co., Ltd.
Just three hours later, Guyu Chun denied the above issues through its official WeChat account, stating that the injectable poly caprolactone microsphere facial filler under the company was a completely self-developed product, and compared to EeenJoy, there are significant differences between the two. In addition, as of the date of the statement, the company has not received any court summons or materials regarding patent infringement lawsuits.
In response to this, Cailian News Agency reporters contacted Guyu Chun, but the company only responded saying "We have a dedicated team of legal consultants handling this on our end."
It is known that the two main characters in this incident, "EeenJoy" and "Suyan Zhen·Zhen Yu", are currently the only two domestically approved "injection poly caprolactone microsphere facial fillers," also known as "Shao Nu Zhen." In 2018, Huadong Medicine acquired Sinclair to obtain Ellansé, and EeenJoy was approved for listing in October 2021 as the first domestic "Shao Nu Zhen", with commercial operation being handled by Xin Keli. The core components of this product are PCL poly caprolactone microspheres and CMC carboxymethyl cellulose, with PCL microspheres accounting for 33.1% by mass.
On the other hand, Cai Cai Medical's Suyan Zhen was approved in China on August 27th this year, being the first domestic "Shao Nu Zhen", with its main core components being PCL poly caprolactone microspheres and CMC carboxymethyl cellulose, and PCL microspheres accounting for 30% by mass.
Ruiwo Bio's chairman Lu Wenqi analyzed in an interview with Caixin reporters that it is currently difficult to determine whether Gu Yu Chun's behavior constitutes infringement. Compared with pharmaceutical patents, it is difficult to define patents for medical beauty products. The behavior of Huadong Medicine may be aimed at protecting intellectual property on one hand, while also hoping to generate publicity through this commercial market behavior, attract more attention, and emphasize its own market position.
"In the past, there was only one product from Huadong Medicine, Eva Shu, now there are domestic teenage vaccination products emerging." Lu Wenqi said, "From the market perspective, currently Eva Shu is priced high, mainly targeting high-end consumers, but in reality, there are more people who need to use this product, so there are more affordable or even better performing products entering the market to meet different consumer needs. However, with more and more companies entering this field in the future, the competition will become more intense. If efforts are not made in terms of product quality and differentiation, there will be continuous intensification of competition."
